No Data
No Data
No Data
No Data
No Data
Buy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline Potential
TipRanksApr 30 21:06
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections
Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results
GlobeNewswireApr 30 19:00
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report
GlobeNewswireApr 24 19:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), PolyPid (PYPD) and Eli Lilly & Co (LLY)
TipRanksApr 15 16:20
PolyPid Ltd. 13G Filing Shows Rosalind Advisors, Inc. Reported A 9.95% Stake In The Co As Of February 13, 2024
PolyPid Ltd. 13G Filing Shows Rosalind Advisors, Inc. Reported A 9.95% Stake In The Co As Of February 13, 2024
BenzingaMar 2 01:53
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company
GlobeNewswireFeb 28 20:00
No Data
No Data